Radiation injuries protective agent - RadioMedix
Alternative Names: AminoMedix™Latest Information Update: 22 Feb 2022
At a glance
- Originator RadioMedix
- Class Amino acids; Chemoprotectants; Drug conjugates; Organothiophosphorus compounds; Peptides; Radiopharmaceuticals; Radioprotectives; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Radiation injuries
Most Recent Events
- 22 Feb 2022 Phase-II clinical development is ongoing in Radiation injuries (Prevention) in USA
- 22 Feb 2022 Phase-II clinical trials in Radiation injuries (Prevention) in USA (IV) (RadioMedix pipeline, February 2022)
- 20 Oct 2016 Phase-I/II clinical trials in Radiation injuries (Prevention) in USA (IV)